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Background
Interleukin-33 (IL-33) is a novel cytokine that triggers
inflammatory immune responses, but evidence of its role
in human asthma, a common allergic airway disease, is
lacking. There is also a paucity of information regarding
which cells express IL-33, and what conditions promote
its expression. We sought to investigate whether IL-33 is
expressed in the lung tissue from patients with asthma.
Methods
We obtained lung biopsy tissue specimens from asth-
matic adults and from healthy control subjects, along
with normal primary cells from human airways that
were cultured in vitro. We studied expression of IL-33
in lung tissue specimens, and determined whether con-
ditions seen in asthma promote IL-33 expression in
vitro. We also assessed whether IL-33 expression is sen-
sitive to glucocorticoid treatment.
Results
Higher expression of IL-33 is detected in lung tissue
from asthmatic patients compared to control subjects.
IL-33 expression correlates TNF-a e.g. a hallmark of
inflammation. Airway epithelium, smooth muscle cells
and endothelium are all sources of IL-33. When exposed
to inflammatory conditions, in vitro cultured bronchial
smooth muscle and epithelial cells increased their IL-33
expression, which surprisingly remained intracellular.
Finally, glucocorticoid did not significantly reduce TNF-
a-induced IL-33 expression.
Conclusions
Our study first describes IL- 3 3e x p r e s s i o ni na s t h m a ;i t
is increased in the lungs from asthmatics, and is
enhanced under asthma-like in vitro conditions. IL-33
originates from structural cells of the airways and its
expression does not respond to classic anti-inflamma-
tory drug, thus reinforcing its relevance as a potential
therapeutic target to treat asthma.
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